Pharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells

Gergely Becs a, Abolfazl Zarjoub, Anupam Agarwal b, Katalin Éva Kovács a, Ádám Becs a, Mónika Nyitrai a, Enikó Balogh c, Emese Bányai c, John W. Eaton d, Paolo Arosio e, Maura Poli e, Viktória Jeney a, József Balla a, György Balla c, f

Abstract

Vascular calcification is a frequent complication of atherosclerosis, diabetes and chronic kidney disease. In the latter group of patients, calcification is commonly seen in tunica media where smooth muscle cells (SMC) undergo osteoblastic transformation. Risk factors such as elevated phosphorus levels and vitamin D3 analogues have been identified. In the light of earlier observations by our group and others, we sought to inhibit SMC calcification via induction of ferritin. Human aortic SMC were cultured using β-glycerophosphate with activated vitamin D3, or inorganic phosphate with calcium, and induction of alkaline phosphatase (ALP) and osteocalcin as well as accumulation of calcium were used to monitor osteoblastic transformation. In addition, to examine the role of vitamin D3 analogues, plasma samples from patients on haemodialysis who had received calcitriol or paricalcitol were tested for their tendency to induce calcification of SMC. Addition of exogenous ferritin mitigates the transformation of SMC into osteoblast-like cells. Importantly, pharmacological induction of heavy chain ferritin by 3H-1,2-Dithiole-3-thione was able to inhibit the SMC transition into osteoblast-like cells and calcification of extracellular matrix. Plasma samples collected from patients after the administration of activated vitamin D3 caused significantly increased ALP activity in SMC compared to the samples drawn prior to activated vitamin D3 and here, again induction of ferritin diminished the osteoblastic transformation. Our data suggests that pharmacological induction of ferritin prevents osteoblastic transformation of SMC. Hence, utilization of such agents that will cause enhanced ferritin synthesis may have important clinical applications in prevention of vascular calcification.

Keywords: ferritin • ferroxidase activity • β-glycerophosphate • vascular calcification • vitamin D3

Introduction

Cardiovascular disease remains the major cause of mortality in patients with chronic kidney disease (CKD) [1–3]. In this regard, vascular calcification continues to be a significant clinical challenge with detrimental consequences and its prevalence and progression is rapidly accelerated once patients require renal replacement therapy [4]. Two distinct forms of vascular calcification have been identified: intimal and medial calcification. The intimal calcification is commonly seen in atherosclerotic lesions, whereas calcification of the tunica media, also known as Monckeberg’s sclerosis, frequently accompanies ageing, diabetes mellitus and advanced CKD [5]. The medial calcification was once thought to be a passive and benign finding, however, a strong body of evidence now suggests that medial calcification is a major cause of mortality and morbidity as it causes vascular stiffness, increases afterload with subsequent hypertrophy of the left
ventricle and compromise of coronary perfusion [6]. Moreover, the process of calcification of the vascular tree is now proven to be a delicate and regulated cellular process that entails transdifferentiation of SMC into osteoblast-like cells. One of the markers of this transition is up-regulation of ALP [7, 8]. Alkaline phosphatase is a hydrolase enzyme that is important in early osteogenesis and has been demonstrated to hydrolyse and reduce the levels of a key inhibitor of hydroxyapatite formation namely, extracellular pyrophosphate. Given its function and the fact that its induction has been shown to be a major determinant of osteoblastic differentiation of SMC, ALP expression is commonly used as a surrogate to monitor the initiation and degree of vascular calcification [8]. Transition of SMC into osteoblast-like cells is also indicated by the increase in expression of osteocalcin, a major non-collagenous protein found in bone matrix which is believed to regulate mineralization [7]. Several promoters and inhibitors are now identified that are actively involved in commencing and propagation of vascular calcification [9]. One of the most potent recognized inducers of vascular mineralization is elevated phosphorus (Pi) level. There is compelling evidence from clinical, animal and in vitro studies that hyperphosphataemia is a significant risk factor for the development of vascular calcification in CKD patients [10–13]. Another culprit that has been shown to induce calcification of SMC is excess of activated form of vitamin D although different forms of vitamin D have been shown to have different degree of effects on vascular calcification [14, 15].

Previously, we investigated whether induction of haeme oxygenase-1/ferritin system alters high Pi-induced SMC calcification in vitro. We found that iron (regardless of its ferric or ferrous state) released from the haeme moiety attenuates calcium deposition of SMC in a dose-responsive manner when SMC are cultured in the presence of high Pi [16]. Further studies revealed that iron-induced ferritin heavy chain (FtH) expression was responsible for the observed inhibitory effects on calcium deposition. This notion was corroborated by utilizing recombinant FtH protein and its mutant form [16, 17]. We found that while addition of FtH (devoid of iron) was able to prevent mineralization, the mutant form that lacks ferroxidase activity was ineffectual. Severe decline in renal function and renal replacement therapy requirement are commonly associated with not only hyperphosphataemia but also iron deficiency [18]. Major contributing factors to such iron deficiency include blood loss during haemodialysis, bleeding of cannula puncture sites following haemodialysis and too frequent diagnostic blood tests. Moreover, during chronic inflammatory diseases (such as CKD) there is an overproduction of a number of cytokines that exert multiple functions including increased production of hepcidin that in turn leads to the degradation of ferroportin (membrane iron transporter) [19]. The overall effect translates to a ‘functional iron deficiency’ state which subsequently leads to decreased intracellular ferritin levels. Therefore, based on our previous studies we concluded that iron deficiency and the ensuing decrement in intracellular FtH expression facilitates vascular calcification in this group of patients and it has been suggested that overexpression of FtH would have inhibitory properties against mineralization of the vasculature in advanced CKD. However, based on iron’s ability to readily accept or donate electrons, it is well known that iron overload and saturation of its sequestration threshold could lead to the generation of reactive oxygen species and consequent injurious effects [20]. Hence, we sought to investigate whether 1,2-dithiole-3-thione (D3T), a potent inhibitor of chemical-induced tumours and a strong inducer of ferritin [21, 22], could be used to prevent calcification and osteoblastic differentiation of SMC. 1,2-dithiole-3-thione has been shown to induce ferritin expression irrespective of iron concentrations via transcriptional mechanism that is mediated by the FtH electrophile/antioxidant responsive element [22].

To examine this hypothesis we used human aortic SMC and induced calcification by utilizing β-glycerophosphate (BGP) with vitamin D3 analogues, as well as Pi with calcium.

Materials and Methods

Reagents

Calcitriol for in vitro experiments was purchased from Cayman Chemicals (Ann Arbor, MI, USA) and fetal bovine serum (FBS) from Life Technologies (Vienna, Austria). Recombinant ferritin subunits: H, L, H222 mutant were provided by Dr. Paolo Arosio (Department M.I. and Biomedical Technologies, University of Brescia, Brescia, Italy). Protease inhibitor tablets were from Roche (Mannheim, Germany). Paricalcitol (Zemplar®) and calcitriol (Calcijex®) for in vivo experiments were purchased from commercial source. Unless otherwise mentioned, all other reagents were purchased from Sigma-Aldrich.

Cell culture

Human aortic SMC were obtained from Cell Applications (San Diego, CA, USA), Lonza (Allendale, NJ, USA), Cambrex (Wokingham, UK). We used human SMC from one to five independent donors for our experiments. We designated the number of independent donors used for each figures that were more than one. Cells were grown in high glucose DMEM containing 15% FBS, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin and neomycin (growth medium, GM). Cells were grown to confluence and used from passages 5 to 7. Media were changed every 2 days.

Alkaline phosphatase activity assay

Cells were grown on twelve-well plates for 7 days. Cells were washed with PBS twice and then solubilized with solubilization buffer [1% Triton X 100, 0.5% Igepal CA-630, 1% protease inhibitor, 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 10 mM Tris]. The assay was performed by adding 35 µl sample to 130 µl of ALP Yellow Liquid Substrate and the kinetics of p-nitrophenol formation was followed up for 30 min. at 405 nm incubating at 37°C. Maximum slope of the kinetic curves was used for calculation and the results were normalized to protein content.

Alkaline phosphatase activity staining

Cells were grown on 48-well plates for 7 days. Staining was done using the 85L3R kit from Sigma-Aldrich. Briefly, cells were washed with PBS...
twice and fixed with citrate-acetone (2:3) solution. After fixation, cells were washed with ddH2O twice. Staining step was performed with Fast violet B salt containing 4% naphthol AS-MX for 30 min. in dark. After staining, cells were washed again with ddH2O and images were obtained.

**Quantification of calcium deposition**

Cells grown on 48-well plates were washed twice with PBS and decalcified with 0.6 mol/l HCl for 24 hrs at 37°C. Calcium content of the supernatants was determined by the QuantiChrome Calcium Assay Kit (Gentaur, Brussels, Belgium). After decalcification, cells were solubilized with a solution of NaOH 0.1 mol/l and SDS 0.1%, and protein content of samples was measured with (bicinchoninic acid) BCA protein assay kit (Pierce, Rockford, IL, USA). Calcium content of the cells was normalized to protein content and expressed as µg/mg protein. Mineralization was also determined by Alizarin Red staining. Briefly, cells grown on 48-well cell culture plates were washed with PBS and fixed with 4% paraformaldehyde. Plates were incubated for 10 min. in RT. Cells were washed with PBS and then stained with 2% Alizarin Red solution for 2 min. After the incubation cells were washed three times with distilled water and photos were taken under light microscope.

**Quantification of osteocalcin**

Osteocalcin was detected from the extracellular matrix of cells grown on six-well plates and was dissolved in 300 µl of EDTA [0.5 mol/l (pH 6.9)]. Osteocalcin content of the EDTA-solubilized extracellular matrix samples was quantified by ELISA method (Bender MedSystems, Burlingame, CA, USA).

**Western Blot for ALP and FtH**

Western blotting was performed with 10% SDS-PAGE gels and 0.45 µm pore size nitrocellulose membrane (Amersham Biosciences, Little Chalfont, UK). Alkaline phosphatase was detected with a rabbit polyclonal antibody at 1:200 dilution (sc-30203; Santa Cruz Biotechnology, Dallas, TX, USA) followed by HRP-labelled anti-rabbit IgG secondary antibody (sc-25617; Santa Cruz Biotechnology) and secondary antimouse IgG antibody (Amersham Biosciences) was used at 1:15,000 dilution. Antigen–antibody complexes were visualized with the horseradish peroxidase chemiluminescence system (Amersham Biosciences). Membranes were reprobed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Mouse anti-GAPDH (NB300-221; Novus Biologicals, Littleton, CO, USA) at 1:1000 and secondary antimouse IgG (Amersham Biosciences) at 1:15,000 dilution were used.

**Quantitative reverse transcription-polymerase chain reaction**

Cells were grown on six-well plates and total RNA was isolated with RNA-STAT60 (Tel-Test Inc, Friendswood TX, USA). SuperScript III reverse transcriptase kit (Invitrogen, Carlsbad, CA, USA) with oligo(dT) (Promega, Madison, WI, USA) was used for reverse transcription. Alkaline phosphatase mRNA expression was determined by multiplex TaqMan Gene Expression Assays and was normalized to GAPDH (ALP: Hs00758162_m1; GAPDH: Hs99999905_m1; Applied Biosystem, Foster City, CA, USA). A total of 20 µl of reaction mixture contained 10 µl TaqMan Gene Expression Mastermix (Applied Biosystem) and 1 µl of assays from target and housekeeping gene was completed with 8 µl of depc-treated water. Reverse transcriptions and qPCRs were carried out using the C1000 Thermal Cycler with CFX 96 Real Time PCR System (Bio-Rad, Hercules, CA, USA).

**FtH siRNA transfection**

Small interfering RNA specific to FtH and negative control siRNA were obtained from Ambion (Austin, TX, USA). Smooth muscle cell transfection with siRNA was achieved using the Oligofectamine Reagent (Invitrogen). Briefly, the cells were plated overnight to form 60–70% confluent monolayers. Ferritin heavy chain siRNA at 30 nmol/l and transfection reagent complex were added to the cells in serum-free medium for 4 hrs. Fresh normal GM was later added and the cells were incubated for another 20 hrs.

**In vivo study with different vitamin D receptor (VDR) activators**

This study included five patients with end-stage renal disease (ESRD) who receive intermittent haemodialysis on a regular schedule three times a week and suffer from secondary hyperparathyroidism. All patients met the criteria for paricalcitol and calcitriol medication as suggested by the guidelines of the Hungarian Society of Nephrology. Anticoagulated blood samples were collected after the routine dialysis before and 10 min. after the administration of drugs. The blood samples were centrifuged at 2000 × g for 10 min. Plasma of the blood samples were collected and kept frozen until the time of experiments when they were added to the medium. Specifically cells were treated by a 50% ratio of patient’s plasma and 50% of growing media without FBS for 5 days. Samples collected after the drug administration were used with or without addition of apoferritin for assessing ALP activity, thus exposure of SMC of apoferritin lasted 5 days as well. The study design and patient care were reviewed and permission was obtained by the Ethics Committee of the University of Debrecen and the Hungarian Government.

**Statistical analysis**

Statistical analysis was performed with GraphPad Prism 5 and by one-way ANOVA test followed by post hoc Bonferroni’s Multiple Comparison test. A significant value of *P* < 0.05 was marked with *, **P** < 0.01 with ** and ***P*** < 0.001 was marked with ***. Non-significant (ns) differences were also marked. Data are shown as mean ± SD.

Statistical analysis for Figure 9C was performed employing Statistica for Windows. The variables were characterized by descriptive analyses (case number, median, quartiles). After comparing the results with Friedman ANOVA, we used Wilcoxon matched pair test with Bonferroni correction to collate the paired samples. *P* ≤ 0.05 was considered significant.
Results

β-glycerophosphate and activated vitamin D₃ promote osteoblast-like transformation of vascular SMC

Our first goal was to test the osteoblast-like transformation of human aortic SMC induced by BGP and activated vitamin D₃ (Calcitriol). Both inducers have the ability to increase ALP activity in dose-dependent manner. As expected we found that combined treatment resulted in higher enzyme activity of ALP (Fig. 1A). The induction of enzyme activity was time-dependent leading to a pronounced elevation at 7 days of exposure (Fig. 1B). Therefore, in our studies the expression of ALP in human SMC was assessed at 7 days. Staining for ALP activity showed increased number of positively stained cells following treatment with BGP or calcitriol alone or together (Fig. 1C). Western blots confirmed that the increased activity was because of the increment of ALP expression. β-glycerophosphate and calcitriol increased the enzyme level dose-dependently and the additive effect is also evident in this representative experiment (Fig. 1D). Expression of ALP protein was also estimated using immunofluorescence staining. Untreated cells were almost completely negative with this staining, whereas cells exposed to BGP and/or calcitriol show increased fluorescence signal indicating higher expression. The cytoskeleton was counterstained for fibrillar actin (Fig. 1E).

Ferritin mitigates induction of ALP activity

Human aortic SMC were treated with BGP and calcitriol alone or in combination to investigate the induction of ALP in the presence or absence of apo- and holoferritin. Both forms of ferritin decreased the activity of ALP and our findings show that there were no significant differences between the two forms (Fig. 2A). Based on this result that elaborates both forms of ferritin are capable of marked inhibition of ALP expression induced either by BGP or activated vitamin D₃, the subsequent experiments were performed with the combination of both BPG and vitamin D₃.

As ferritin shell is made of both the H and L chains and to delineate the individual effects of each form of ferritin, we performed the following experiment using H- (FH) and L- recombinant ferritin. Furthermore, we also utilized the H222 mutant form of FH which is identical to the FH, but lacks ferroxidase activity based on the mutation [23]. Alkaline phosphatase activity assays showed that inhibition of transformation only occurred when cells were pre-incubated with FH chain, whereas L chain and H222 (both of which lack ferroxidase activity) had no effect (Fig. 2B).

Alkaline phosphatase staining of treated cells showed increased number of positively stained cells treated with both inducing agents versus untreated cells. Addition of either apo- or holoferritin led to significant inhibition of ALP induction. In addition, ferritin subunits were also used in staining assays to show the inhibitory effect of ferroxidase activity. Inhibition of transformation only occurred when cells were pre-incubated with ferroxidase-active H chain (Fig. 2C).

To determine whether the effects of exposure of cells to exogenous ferritins were specific for ferritin per se (as opposed to effects which might be mediated by the fluid phase endocytosis of exogenous ferritin), cells were also pre-exposed to iron (in the form of ferric ammonium citrate) which induces ferritin synthesis by increasing intracellular iron (Fig. 3B). The treatment of cells with iron and subsequent induction of ferritin resulted in mitigation of BGP and calcitriol-induced ALP induction (Fig. 3A).

The specific involvement of ferritin in the prevention of ALP induction is supported by experiments using siRNA. Again, we exposed cells to ferric ammonium citrate, but in this case, inhibited ferritin synthesis using anti-FH siRNA. The suppression of FH induction abrogated the blockade of ALP induction which proceeded in cells which had not been pre-treated with BGP and calcitriol (Fig. 3C). Therefore, these results demonstrate that FH induction – irrespective of the mode and whether via fluid phase endocytosis of exogenous FH or induction of FH synthesis caused by exposure to additional iron in the culture medium – directly prevents ALP expression and activity which normally occurs under conditions favouring calcification. We also confirmed the efficiency of siRNA, and observed an approximately 80% decrease in FH protein expression for up to 4 days after transfection (Fig. 3D).

Besides iron, which is the physiological inducer of ferritin, other agents could also be utilized to induce endogenous ferritin expression. We chose the 3H-1,2-Dithiole-3-thione (D3T). Human aortic SMC treated with increasing dose of D3T in the presence of BGP and calcitriol showed lower activity of ALP, and the decreased enzyme activity showed an inverse relationship with the increasing dosage of D3T (Fig. 4A). We confirmed induction of FH as a dose-dependent response to D3T administration (Fig. 4B). To demonstrate that FH induction by D3T is responsible for the inhibitory effect on ALP expression in SMC, we transfected cells with siRNA for FH and measured ALP enzyme activity. Indeed, ALP activity was not attenuated in D3T-treated SMC grown in BGP and calcitriol containing media after silencing FH (Fig. 4C). The efficiency of silencing FH was approximately 70% (Fig. 4D) in our experiment.

Elucidation of mechanism of inhibition of human aortic SMC differentiation to osteoblasts

We next sought to investigate the mechanism by which FH provides inhibitions of ALP and hence osteoblastic transformation of SMC. In vitro measurement of enzyme activity was performed for which cells were treated with BGP and calcitriol for 7 days and then solubilized. Supernatant of cell lysates were exposed to the effect of apo- and holoferritin. Levamisole, a well-known inhibitor of ALP was used to illustrate the inhibition. We found that such a treatment did not result in inhibition of ALP activity and hence results suggest that ferritin does not directly alter ALP enzyme activity (Fig. 5A).

We then examined protein expression by Western blot. Cells treated with calcifying media showed increased ALP expression,
whereas both apo- and holoferritin diminished the induction (Fig. 5B). Moreover, we show that ferritin molecules can inhibit the increased level of ALP protein visualized with immunofluorescence staining (Fig. 5C).

Next, we examined the possibility of observed inhibitory effects at transcriptional level utilizing RT-PCR. mRNA expressions of ALP in samples were measured and normalized by GAPDH and the fold increase to growth media was calculated. We show that calcifying condition resulted in up-regulation of ALP mRNA. Results revealed that both apo- and holoferritin significantly decreased ALP mRNA levels (Fig. 5D). These results indicate that regulation of ALP expression in SMC by ferritin occurs at transcriptional level.

Ferroxidase activity is the key inhibitory mediator of osteoblastic transformation

Ceruloplasmin is a copper-binding and carrier protein that is mainly produced by hepatocytes. However, for the purposes of our experiments it served as an important control arm as it, similar to FTH, possesses ferroxidase activity. Ferroxidase activity of ceruloplasmin dose-dependently inhibited the ALP activity enhanced by osteoblastic inducers (Fig. 6A). Induction of ALP by calcitriol alone was also inhibited by ceruloplasmin by 70%. Staining experiments also demonstrated further evidence supporting the inhibitory role of ferroxidase activity (Fig. 6B). The decreased activity was caused by
the lowered protein expression, which was detected by Western blot analysis (Fig. 6C).

**Inhibition of human aortic SMC mineralization by heavy chain ferritin**

Although the expression of ALP as an early marker of mineralization was increased after exposure of human SMC to BGP and calcitriol mineralization did not occur even if cells from five independent donors were cultured for up to 3 weeks. This is in accordance with the literature – bovine SMC are mostly employed in calcification studies as they are more ready to mineralize as compared to human SMC. To demonstrate that by up-regulating ferritin by iron or D3T inhibits not only the expression of ALP, but it affects calcification as well in human SMC, we exposed human aortic SMC to 1.2 mmol/l Pi and 0.9 mmol/l calcium (calcification medium) and performed Alizarin red staining as well as measured the calcium accumulation. Granular deposits developed in cells grown in calcification medium, but not in the control culture grown in normal GM (Fig. 7A and D), as demonstrated by Alizarin red staining. We found that addition of iron or D3T to the calcification medium suppresses granular deposit development (Fig. 7A and D) and extracellular calcium deposition in a dose-responsive manner (Fig. 7B and E), causing marked inhibition at concentrations of 25 and 50 μmol/l, respectively. As iron is a very potent inducer of ferritin and D3T also markedly enhances the intracellular ferritin content (Figs 3 and 4), next we tested whether the observed inhibitory effect of iron or D3T on calcium deposition is mimicked by apoferritin. We found that iron-free apoferritin at a dose of 2 mg/ml abolishes granule formation (Fig. 7A) and inhibits calcium deposition (Fig. 7B). To confirm the inhibitory effect of iron or D3T on calcium accumulation occurs via FtH, we transfected human SMC with small interfering RNA specific to FtH. We observed an approximately 70% efficiency in FtH silencing (Fig. 8E). As we exposed cells to ferric ammonium citrate or D3T the suppression of FtH induction resulted in abrogation of the inhibition of calcium accumulation (Fig. 8A and C). This result indicates that the elevation of intracellular FtH by iron or D3T is the main mediator of inhibition of the calcification of extracellular matrix.

Next we investigated the presence of the bone-specific protein, osteocalcin, in the extracellular matrix. Maintaining of human SMC in calcification medium for 7 days resulted in a significant increase in
osteocalcin content compared to the control Figure 7C and F. Iron or D3T decreased the up-regulation of osteocalcin in a dose-responsive manner (Fig. 7C and F). In addition, apoferritin also abolished expression of osteocalcin (Fig. 7C). As we silenced FtH in human SMC treated with ferric ammonium citrate or D3T (Fig. 8E) the inhibition of osteocalcin accumulation in extracellular matrix was abrogated (Fig. 8B and D). Taken together, intracellular ferritin induction is a major inhibitory mediator of calcification and transdifferentiation of SMC.

Vitamin D3 receptor agonist in the osteoblastic transformation

Paricalcitol was able to increase the activity of ALP in human aortic SMC and the inducing effect was dose-dependent (Fig. 9A). Ferroxidase activity of apo- and holoferritin inhibited the increased ALP enzyme activity induced by paricalcitol (Fig. 9B).

In vivo study with different VDR activators and ferritin

Plasma samples from patients with ESRD and secondary hyperparathyroidism who were treated with calcitriol or paricalcitol were collected and added to human aortic SMC. After 5 days, calcitriol significantly increased enzyme activity, and apoferritin abrogated this induction. Paricalcitol also significantly induced the activity of ALP albeit to a lesser degree. Again, addition of ferritin lowered ALP activity to baseline level irrespective of the inducer (Fig. 9C).

Discussion

The findings presented in this study corroborate the inhibitory role of FtH in the inhibition of SMC mineralization and osteoblastic transformation. To induce mineralization we used BGP with or without the addition of calcitriol. These experiments confirmed previous reports.
identifying elevated Pi and high levels of activated vitamin-D (calcitriol) as inducers of calcification of SMC [15, 24, 25]. We used ALP expression as a surrogate of SMC transition to osteoblasts as previously reported [8]. We validated that FtH prevents calcification and osteoblastic transformation of SMC, irrespective of the inducers used in this study. In this regard, ferroxidase activity was confirmed to be essential in the mitigation of calcification. We used D3T, a well-known chemo-preventive agent that is known to induce ferritin expression [21, 22]. We demonstrate that induction of ferritin via D3T abrogates SMC transition to osteoblasts and therefore prevents calcification of extracellular matrix (Fig. 10). Furthermore, we found that culture of SMC with serum samples from ESRD patients receiving calcitriol or paricalcitol leads to osteoblastic transition and we also show that addition of FtH prevents such transition.

Cardiovascular disease remains the leading cause of death in patients with advanced CKD and ESRD [2, 26, 27]. Evidence suggests that adjusted cardiovascular attributed mortality is higher by about 10–20-fold in CKD patients compared to the general population [28]. The increased prevalence of cardiovascular disease in this group of patients is, at least in part, attributable to vascular calcification [29]. Increased prevalence of this condition in the younger patient population requiring renal replacement therapy is a strong confirmation that the uraemic milieu generates the perfect storm for initiation and acceleration of vascular calcification [30, 31]. Increased Pi level is a significant risk factor and has been confirmed in multiple studies to be a key regulator of vascular calcification [32]. Other inducers of vascular calcification have also been identified [33]. The vitamin D receptor analogues have been shown to induce mineralization of the vascular tree as well. However, different analogues have been shown to exert variable results [4, 14]. Importantly, calcitriol and its analogues are routinely used to manage secondary hyperparathyroidism that is a frequent complication of end-stage kidney disease. The SMC are known to express vitamin-D receptor that is up-regulated by calcitriol. Furthermore, previous studies indicate that calcitriol can exert multiple effects on the proliferation and differentiation of SMC. In addition, it has been demonstrated that supraphysiological doses of calcitriol can induce vascular calcification in both in vitro and animal...
models [34]. It is suggested that calcitriol increases SMC mineralization by increasing the RANKL/osteoprotegerin ratio [14]. Based on the above mentioned evidence we used Pi and calcitriol to induce osteoblast transition of SMC.

Ferritin is an ancient, large, spherical protein with highly conserved three-dimensional structure and is the most important intracellular machinery [35, 36]. The ferritins are a family of proteins similar to spherical shells, designed to sequester and store iron.

Fig. 5 Elucidation of mechanism of inhibition of smooth muscle cells (SMC) differentiation to osteoblasts. (A) SMC were treated with β-glycerophosphate (BGP) (10 mmol/l) and activated vitamin D₃ (calcitriol) (10 nmol/l) for 7 days and the cell lysates was used for in vitro measurements. Apo- and holoferritin in addition to levimazole, a well-known ALP inhibitor was used to evaluate the direct effects on enzyme activity. Enzyme activity was measured in duplicate, ***P < 0.001. SMC were cultured in growth medium (GM) or in the presence of BGP (10 mmol/l) and calcitriol (10 nmol/l) with additional apo- or holoferritin (2 mg/ml) for 7 days. (B) Alkaline phosphatase enzyme activity was measured, and the results were normalized by protein content and data show the average of two separate experiments performed in duplicate. **P < 0.01, ***P < 0.001. (C) Images were selected, magnification 100×. (D) Alkaline phosphatase mRNA expression was detected by RT-PCR and results were normalized by GAPDH mRNA content and data show the average of two separate experiments performed in duplicate. **P < 0.01, ***P < 0.001.

Fig. 6 Ferroxidase activity of ceruloplasmin also inhibits the differentiation of smooth muscle cells (SMC) to osteoblasts. SMC were treated with β-glycerophosphate (BGP) (10 mmol/l) and activated vitamin D₃ (calcitriol) (10 nmol/l) in the presence of increasing dose of ceruloplasmin (1–3 mg/ml) for 7 days. (A) Alkaline phosphatase enzyme activity was measured, and the results were normalized by protein content and data show the average of two separate experiments performed in duplicate. **P < 0.01, ***P < 0.001. (B) Cells were stained for alkaline phosphatase, enzyme activity, and representative parts of the slides were selected, magnification 100×. (C) Alkaline phosphatase enzyme level was detected by Western Blot, and GAPDH served as loading control.
| NK | Calcification medium | Iron | ApoFT |
|----|----------------------|------|-------|
| -  | 12.5µM              | 25µM | 50µM  | 2mg/ml |

**Calcification medium**

| A | 6,25µM | 12,5µM | 25µM | 50µM |
|----|--------|--------|------|------|

**Calcification medium**

| B | 6,25µM | 12,5µM | 25µM | 50µM |
|----|--------|--------|------|------|

**Calcification medium**

| C | 6,25µM | 12,5µM | 25µM | 50µM |
|----|--------|--------|------|------|

**Calcification medium**

| D | 6,25µM | 12,5µM | 25µM | 50µM |
|----|--------|--------|------|------|

**Calcification medium**

| E | 6,25µM | 12,5µM | 25µM | 50µM |
|----|--------|--------|------|------|

**Calcification medium**

| F | 6,25µM | 12,5µM | 25µM | 50µM |
|----|--------|--------|------|------|
Fig. 7 Mineralization of vascular smooth muscle cells induced by inorganic phosphate and calcium is inhibited by induction of ferritin. Calcification occurred by supplementation of growth medium (GM) with 1.2 mmol/l inorganic phosphate and 0.9 mmol/l calcium chloride. (A) Alizarin Red staining of the cells shows the mineralization process and the inhibition by increasing dose of iron and apoferritin. (B) Iron inhibits extracellular calcium deposition of human aortic smooth muscle cells (SMC) in a dose-dependent manner, where apoferritin also prevents mineralization. Calcium content of the cells was measured at 5 days and normalized by the protein content of the cells. (C) Iron and apoferritin attenuate up-regulation of osteocalcin induced by calcifying condition. SMC were cultured in GM or in calcification medium with increasing dose of ferric-(III)-ammonium citrate (12.5–25–50 μmol/l) or 2 mg/ml apoferritin for 5 days. Data is derived from four separate experiments are shown as mean ± SD, **P < 0.01; ***P < 0.001. (D) Representative images of SMC with Alizarin red staining indicating the inhibition of mineralization with increasing dose of 3H-1,2-Dithiole-3-thione (D3T). SMC were cultured in GM or in calcifying condition as described above or supplemented with 6.25, 12.5, 25 and 50 μmol/l D3T during 5 days. Exposure of SMC to D3T decreased the accumulation of calcium (E) and osteocalcin levels (F) in a dose-responsive manner. Graphs are shown mean ± SD of three separate experiments. **P < 0.01; ***P < 0.001. [Correction added on 26 January 2016 after first online publication: Figure 7 was presented incorrectly and has been amended in this version.]

Fig. 8 Ferritin heavy chain (FtH) is the main modulator of inhibition of mineralization of vascular smooth muscle cells. Smooth muscle cells (SMC) were transfected with siRNA for FtH or negative control siRNA (NC) 24-hr before the experiments. Cells were cultured in growth media (GM) or calcifying media (additional 1.2 mmol/l inorganic phosphate and 0.9 mmol/l calcium to GM) alone or in the presence of 25 μmol/l ferric-(III)-ammonium citrate or 50 μmol/l D3T for 4 days. (A) Iron exposure after FtH silencing failed to attenuate calcium and (B) osteocalcin accumulation. (C) D3T treatment after silencing of FtH loses the capacity to inhibit the calcium deposition and (D) osteocalcin accumulation in extracellular matrix. (E) Western blot demonstrates the efficiency of FtH silencing. GAPDH served as loading control. Results are shown as mean values ± SD. ***P < 0.001.
large amounts of iron in a safe, soluble and bioavailable form. Ferritin is made of 24 subunits of two types (H, heavy and L, light chain) whose proportion depends on the iron status of the cell, the tissue and the organ. The two ferritin polypeptides are related, but FtH carries a ferroxidase activity to oxidize Fe²⁺ to Fe³⁺ allowing safe incorporation of iron into the shell. Ferritin shells can store up to 4500 iron atoms. Ferritin acts as a depot, sequestering excess iron and allowing for the mobilization of iron when needed [35, 36]. Our understanding of ferritin and its functions has markedly enhanced in the past decade and novel functions other than regulation of iron metabolism and homeostasis are now attributed to ferritin [16, 37–41].

Previously, we reported that haeme and iron-mediated induction of FtH prevents calcification and osteoblastic differentiation of SMC induced by high Pi [16]. We reported that ferroxidase activity of FtH was the key mediator of the observed inhibitory effects [16]. Importantly, we previously found that the induction of FtH was able to

Fig. 9 Vitamin D analogues increases the osteoblastic transformation of vascular smooth muscle cells (SMC). (A) SMC were cultured in growth medium (GM) or in the presence of activated vitamin D₃ (calcitriol) (10 nmol/l) or with increasing dose of paricalcitol (1–4–10–40–100 nmol/l) for 7 days. Alkaline phosphatase enzyme activity was measured, and the results were normalized by protein content and data show the average of the triplicates, ***P < 0.001. (B) SMC were cultured in GM or in the presence of paricalcitol (40 nmol/l) with additional apo- or holoferritin (2 mg/ml) for 7 days. Enzyme activity was measured, and the results were normalized by protein content and data show the average of two separate experiments performed in duplicate, ***P < 0.001. (C) Plasma samples from volunteers from our dialysis centre were collected right after the haemodialysis session (control) and after the administration of calcitriol/paricalcitol. After the administration of drugs we waited 5 min. to reach a steady-state blood concentration and then the samples were taken. SMC were treated with 1:1 ratio with serum-free media and plasma samples for 5 days. Alkaline phosphatase activity was measured, and the results were normalized by protein content and as a result of the high variability of patients values data show maximum and minimum values besides of the median and interquartile range, experiments were performed in duplicate.

Fig. 10 Suggested mechanism of how induction of ferritin via D₃T prevents smooth muscle cells mineralization. Transition of vascular smooth muscle cells into osteoblast-like cells can be triggered by phosphate [inorganic (Pi), β-glycerophosphate (β-GP)] or activated vitamin D₃ (calcitriol). Pi taken up by sodium-phosphorus co-transporter-1 (Pit-1) activates core binding factor alpha-1 (Cbfa-1) responsible for the expression of osteoblast-specific genes. Induction of ferritin heavy chain with ferroxidase activity by 3H-1,2-Dithiole-3-thione (D₃T) or iron abrogates the elevation of osteoblast-specific genes [transcription factor Cbfa-1, osteocalcin (OC), alkaline phosphatase (ALP)] and the accumulation of calcium in the extracellular matrix.
actively prevent the process of transformation of SMC into osteoblast-like cells and also inhibit osteoblast activity via down-regulation of Cbfa-1 [16, 40], the main transcriptional factor mediating osteogenesis and responsible for the induction of osteoblast-specific gene expression [42]. Furthermore, ferritin did not affect Pi uptake via PiT1 (sodium-phosphorus co-transporter) [16]. These findings were the first report to suggest a relationship between deranged iron metabolism that is a frequent complication of CKD and vascular calcification. Patients who are dependent on renal replacement therapy are susceptible to iron deficiency for a multitude of reasons that include frequent blood loss during haemodialysis and frequent diagnostic testing [43]. Moreover, increased expression and secretion of hepcidin in chronic inflammatory states such as CKD translates to internalization and degradation of ferroportin in lysosomes [44, 45]. The loss of ferroportin from cell membrane consequently ablates cellular iron export. Evidence suggests that increased hepcidin levels can lead to functional iron deficiency and subsequently anaemia by interrupting intestinal iron absorption and inducing the retention of iron within recycling reticuloendothelial macrophages. Therefore, it is evident that CKD patients are at increased risk of developing iron scarcity ensuing by significant decrement in intracellular ferritin expression. We suggested that such decrement exacerbates SMC transition to osteoblasts in the uraemic environment. We were hence encouraged to identify potential pharmacological agents that would be able to induce ferritin expression and examine whether such induction via chemical stimulants of ferritin would provide the same inhibitory effects. To this end we examined the compound D3T that is known to have anti-oxidant and cancer chemopreventive properties. We demonstrate that D3T-induced up-regulation of FTH provides inhibitory effects against high Pi- and calcitriol-mediated osteoblastic differentiation of SMC. It should, however, be noted that D3T is not currently approved for human use. However, it occurs naturally in cruciferous vegetables. The oral administration of D3T is being considered for development as a potential drug for the chemoprevention of hepatic and other carcinomas by the National Cancer Institute.

In conclusion, this study corroborates our previous findings and validates FTH induction as a potent inhibitor of osteoblastic transformation of SMC. Given legitimate concerns regarding utilization of excessive parenteral iron that may potentiate in excessive reactive oxygen species formation, chemical induction of FTH via D3T may be a novel preventive measure against vascular calcification. In support of this premise, further studies to test this hypothesis in relevant animal models of vascular calcification is germane and timely given current lack of reliable preventive and/or therapeutic modalities against vascular calcification.

Acknowledgements

This study was supported by the TÁMOP-4.2.2, A-11/1/KONV-2012-0045 project, by BMC Korea Research Fund, and by grants from Hungarian Scientific Research Fund (OTKA: K 112333 to JB) and Hungarian Academy of Sciences. The research group (VJ, JB, GyB) is supported by the Hungarian Academy of Sciences (11003).

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112–9.
2. Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World J Nephrol. 2014; 3: 156–88.
3. Ardhnari S, Alpert MA, Aggarwal K. Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention. Adv Perit Dial. 2014; 30: 40–53.
4. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009; 20: 1453–64.
5. McCullough PA, Agrawal V, Danielewicz E, et al. Accelerated atherosclerotic calcification and Monckeberg’s sclerosis: a continuum of advanced vascular pathology in chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3: 1585–98.
6. Beadnok WF, Daoud AS, Love BM. Calcification in the coronary arteries and its relationship to arteriosclerosis and myocardial infarction. Am J Roentgenol Radium Ther Nucl Med. 1964; 92: 865–71.
7. Giachelli CM, Stelz S, Jono S. Potential roles of bone matrix proteins in vascular calcification. Clin Calcium. 1999; 9: 20–7.
8. Lomashvili KA, Garg P, Narisawa S, et al. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008; 73: 1024–30.
9. Giachelli CM. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005; 8: 299–31.
10. Giachelli CM, Jono S, Shioi A, et al. Vascular calcification and inorganic phosphate. Am J Kidney Dis. 2001; 38: S34–7.
11. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003; 14: S300–4.
12. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10–7.
13. Shioi A, Nishizawa Y, Jono S, et al. Betaglycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995; 15: 2003–9.
14. Cardus A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res. 2007; 22: 860–6.
15. Henley C, Colloton M, Cattley RC, et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant. 2005; 20: 1370–7.
16. Zarjou A, Jeney V, Arosio P, et al. Ferritin prevents calcification and osteoblastic differentiation of vascular smooth muscle cells. J Am Soc Nephrol. 2009; 20: 1254–63.
17. Cozzi A, Corsi B, Levi S, et al. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells: in vivo role of ferritin ironoxydase activity. J Biol Chem. 2000; 275: 25122–9.
18. Wittwer I. Iron deficiency anaemia in chronic kidney disease. J Ren Care. 2013; 39: 182-8.
19. Huang ML, Austin CJ, Sari MA, et al. Hepcidin bound to alpha2-macroglobulin reduces ferroportin-1 expression and enhances its activity at reducing serum iron levels. J Biol Chem. 2013; 288: 25450-65.
20. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002; 33: 467-63.
21. Kensler TW, Groopman JD, Sutter TR, et al. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol. 1999; 12: 113-26.
22. Pietsch EC, Chan JY, Torti FM, et al. Nrfr2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem. 2003; 278: 2361–9.
23. Broxmeyer HE, Cooper S, Levi S, et al. Mutated recombinant human heavy-chain ferritins and myelosuppression in vitro and in vivo: a link between ferritin ferroxidase activity and biological function. Proc Natl Acad Sci USA. 1991; 88: 770–4.
24. El-Abdali MM, Pai AS, Leaf EM, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009; 75: 1297–307.
25. Lau WL, Leaf EM, Hu MC, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012; 82: 1261–70.
26. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013; 9: 331–9.
27. Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014; 3: 99-104.
28. Kumar S, Bogle R, Banerjee D. Why do young people with chronic kidney disease die early? World J Nephrol. 2014; 3: 143–55.
29. Block GA. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol. 2000; 54: 318–24.
30. Milliner DS, Zinsmeister AR, Lieberman E, et al. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int. 1990; 38: 931–6.
31. Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol. 2013; 38: 136–48.
32. Burke SK. Phosphate is a uremic toxin. J Ren Nutr. 2008; 18: 27–32.
33. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013; 24: 179–89.
34. Ueno Y, Shinki T, Nagai Y, et al. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem. 2003; 90: 267–77.
35. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta. 2009; 1790: 589–99.
36. Finazzi D, Arosio P. Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration. Arch Toxicol. 2014; 88: 1787–802.
37. Alkhateeb AA, Connor JR. Nuclear ferritin: a new role for ferritin in cell biology. Biochim Biophys Acta. 2010; 1800: 793–7.
38. Coffman LG, Parsonage D, D’Agostino R Jr, et al. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA. 2009; 106: 570–5.
39. Zarjeu A, Bolisetty S, Joseph R, et al. Proximal tubule H-ferritin mediates iron trafficking in acute kidney injury. J Clin Invest. 2013; 123: 4423–34.
40. Zarjeu A, Jeney V, Arosio P, et al. Ferritin ferroxidase activity: a potent inhibitor of osteogenesis. J Bone Miner Res. 2010; 25: 164–72.
41. Balla G, Jacob HS, Balla J, et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem. 1992; 267: 18148–53.
42. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997; 89: 755–64.
43. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985; 28: 1–5.
44. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090–3.
45. Singh B, Arora S, Agrawal P, et al. Hepcidin: a novel peptide hormone regulating iron metabolism. Clin Chim Acta. 2011; 412: 823–30.